ENT Updates

Clinical Research

Significance of TNFSF11 and TNFRSF11B in Middle Ear Cholesteatoma of Children and Adults

Downloads

https://doi.org/10.54963/entu.v15i1.847
Tang, S., Ye, M., Liu, Z., Yang, J., Zheng, Z., & Liu, Q. (2025). Significance of TNFSF11 and TNFRSF11B in Middle Ear Cholesteatoma of Children and Adults. ENT Updates, 15(1). https://doi.org/10.54963/entu.v15i1.847
Volume 15 Issue 1 (2025)
Copyright (c) 2025 Susu Tang, Mingyuan Ye, Zhao Liu, Jing Yang, Zhenlin Zheng, Qianxu Liu
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors

  • Susu Tang Department of Otorhinolaryngology, Zhuhai People’s Hospital, Zhuhai 519000, China https://orcid.org/0000-0001-8382-8273
  • Mingyuan Ye Department of Otorhinolaryngology, Zhuhai People’s Hospital, Zhuhai 519000, China https://orcid.org/0000-0002-6130-6797
  • Zhao Liu Department of Otorhinolaryngology, Zhuhai People’s Hospital, Zhuhai 519000, China https://orcid.org/0009-0006-8440-2059
  • Jing Yang 1. Department of Otorhinolaryngology, Zhuhai People’s Hospital, Zhuhai 519000, China; 2. Hearing Impairment and Vertigo Clinic of Zhuhai, Zhuhai Hospital of Integrated Traditional Chinese and Western Medicine, Zhuhai 519000, China https://orcid.org/0000-0001-5021-1007
  • Zhenlin Zheng Department of Laboratory Medicine, Zhuhai People’s Hospital, Zhuhai 519000, China
  • Qianxu Liu
    Department of Otorhinolaryngology, Zhuhai People’s Hospital, Zhuhai 519000, China

Middle ear cholesteatoma is a common ear disease with different manifestations and pathological mechanisms in children and adults.Middle ear cholesteatoma is more severe in children than adults. We aimed to detect the expression of tumor necrosis factor ligand superfamily member 11 (TNFSF11) and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B) and analyze the difference in ear bone destruction in middle ear cholesteatoma in children and adults.Through the comprehensive analysis of related studies, the mechanism of its action in the progression of the disease was expounded, and the theoretical basis for clinical treatment was provided. A total of 18 children and 32 adults with middle ear cholesteatomas were examined. The degree of bone destruction was observed. TNFSF11 and TNFRSF11B expressions in the cholesteatoma and normal external auditory canal skin were detected by immunohistochemistry. Bone destruction was more severe in children with middle ear cholesteatoma. TNFSF11 expression in cholesteatoma was significantly higher in children than adults, whereas expression in external auditory canal skin was not significantly different between groups. Expression of TNFRSF11B in cholesteatoma and external auditory canal skin was not significantly different between children and adults. In children and adults, TNFSF11 in cholesteatomas was not correlated with TNFRSF11B. TNFSF11 expression was positively correlated with the degree of ear bone destruction, unlike TNFRSF11B. TNFSF11 expression in children with cholesteatoma is higher than adults and is involved in the molecular biological mechanism underlying its destructive nature. These findings will help us develop better treatments.

Keywords:

Cholesteatoma of the Middle Ear Skin of the External Auditory Canal Tumor Necrosis Factor Ligand Superfamily Member 11 Tumor Necrosis Factor Receptor Superfamily Member 11B Degree of Ear Bone Destruc‑ tion

References

  1. Dornelles, C.; Meure, L.; Selaimen, D.A.; et al. Histologic Description of Acquired Cholestcatomas: Comparison between Children and Adults. Braz J. Otorhinolaryngol. 2006, 72, 641–648.
  2. Welkoborsky, H.J. Current Concepts of the Pathogenesis of Acquired Middle Ear Cholesteatoma. Laryngorhinootologie 2011, 90, 38–48.
  3. Kuo, C.L. Etiopathogenesis of Acquired Cholestcatoma; Prominent Theories and Recent Advances in Biomolecular Research. Laryngoscope 2015, 125, 234–240.
  4. Chen, A.P.; Wang, B.; Zhong, F.; et al. Expression Levels of Receptor Activator of Nuclearfactor-kB Ligand and Osteoprotegerin are Associated with Middle Ear Cholesteatoma Risk. Acta Oto-Laryngol. 2015, 135, 655–666.
  5. Jackson, R.; Addison, A.B.; Prinsley, P.R. Cholesteatoma in Children and Adults: Are there Really Any Differences?. J. Laryngol. Otol. 2018, 132, 575–578.
  6. Kalia, M.; Dass, A.; Singhal, S.K.; et al. Comparative Study of Cholesteatoma in Paediatric and Adult Patients. J. Laryngol. Otol. 2022, 136, 765–768.
  7. Školoudík, L.; Šimáková, E.; Kalfeřt, D.; et al. Histological Changes of the Middle Ear Ossicles Harvested during Cholesteatoma Surgery. Acta Med. (Hradec Králové) 2015, 58, 119–122.
  8. Grunkin, M.; Raundahl, J.; Foged, N.T. Practical Considerations of Image Analysis and Quantification of Signal Transduction IHC Staining. Methods Mol Biol. 2017, 717, 143–154.
  9. Preciado, D.A. Biology of Cholesteatoma: Special Considerations in Pediatric Patients. Int. J. Pediatr. Otorhinolaryngol. 2012, 76, 319–321.
  10. Iwamoto, Y., Nishikawa, K.; Imai, R.; et al. Intercellular Communication between Keratinocytes and Fibroblasts Induces Local Osteoclast Differentiation: A Mechanism Underlying Cholesteatoma-Induced Bone Destruction. Mol. Cell. Biol. 2016, 36, 1610–1620.
  11. Alves, A.L.; Pereira, C.S.; Ribeiro, F.A.; et al. Analysis of Histopathological Aspects in Acquired Middle Ear Cholesteatoma. Braz. J. Otorhinolaryngol. 2008, 74, 835–841.
  12. Liu, W.; Xie, S.; Chen, X.; et al. Activation of the IL-6/JAK/STAT3 Signaling Pathway in Human Middle Ear Cholesteatoma Epithelium. Int. J. Clin. Exp. Pathol. 2014, 7, 709–715.
  13. Bassiouny, M.; Badour, N.; Omran, A. characteristics of Acquired Cholesteatoma in Children and Adults. Egypt. J. Ear Nose Throat Allied Sci. 2012, 13, 7–12.
  14. Simonet, W.S.; Lacey, D.L.; Dunstran, C.; et al. Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density. Cell 1997, 89, 309–319.
  15. Gori, F.; Hofbauer, L.C.; Dunstan, C.R.; et al. The Expression of Osteoprotegerin and Rank Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells is Developmentally Regulated. Endocrinology 2000, 141, 4768–4776.
  16. Lacey, D.L.; Timmas, E.; Tan, H.L.; et al. Osteopotegerin Ligand is a Cytokine that Regulates Osteoclast Differentiation and Activation. Cell 1998, 93, 165–176.
  17. Yasuda, H.; Shima, N.; Nakagwa, N.; et al. Osteoclast Differentiation Factor is a Ligand for Osteoprotegerin/Osteoclast Genesis-Inhibitory Factor and is Identical to TRANCE/RANKL. Natl. Acad. Sci. 1998, 95, 3597–3602.
  18. Takayanagi, H.; Iizuka, H.; Juji, T.; et al. Involvement of Receptor Activator of Nuclear Factor Kappab Ligand/Osteoclast Differentiation Factor in Osteoclastogenesis from Synoviocytes in Rheumatoid Arthritis. Arthritis Rheum. 2000, 43, 259–269.
  19. Chen, X.; Wang, Z.Q.; Duan, N.; et al. Osteoblast-Osteoclast Interactions. Connect. Tissue Res. 2018, 59, 99–107.
  20. Imai, R.; Sato, T.; Iwamoto, Y.; et al. Osteoclasts Modulate Bone Erosion in Cholesteatoma via RANKL Signaling. J. Assoc. Res. Otolaryngol. 2019, 20, 449–459.
  21. Jeong, J.H.; Park, C.W.; Tae, K.; et al. Expression of RANKL and OPG in Middle Ear Cholesteatoma Tissue. Laryngoscope 2006, 116, 1180–1184.
  22. Chen, X.H.; Qin, Z.B.; Lu, W. Expression of RANK-RANKL-OPG System in Middle Ear Cholesteatoma. Chin. Arch. Otolaryngol. Head Neck Surg. 2009, 16, 579–581.
  23. Sun, H.Y.; Li, Q.H.; Zhang, Y.K.; et al. Regulation of OPG and RANKL Expressed by Human Dental Follicle Cells in Osteoclastogenesis. Cell. Tissue Res. 2015, 362, 399–405.
  24. Fu, D.P.; Qin, K.R.; Yang, S.; et al. Proper Mechanical Stress Promotes Femoral Head Recovery from Steroid-Induced Osteonecrosis in Rats through the OPG/RANK/RANKL System. BMC Musculoskelet. Disord. 2020, 21, 281.
  25. Xie, S.; Wang, X.; Ren, J.; et al. The Role of Bone Resorption in the Etiopathogenesis of Acquired Middle Ear Cholesteatoma. Eur. Arch. Otorhinolaryngol. 2017, 274, 2071–2078.
  26. Li, Y.L.; He, M.; Chen, B.X.; et al. OPG-RANKL-RANK Signaling System is an Important Approach to Regulate Osteoclasts and Osteoporosis. Chin. J. Tissue Eng. Res. 2015, 19, 3894–3898.
  27. Yasuda, H. Discovery of the RANKL/RANK/OPG System. J. Bone Miner. Metab. 2021, 39, 2–11.
  28. Liu, W.; Zhang, X.L. Receptor Activator of Nuclear Factor-κB ligand (RANKL)/RANK/osteoprotegerin system in Bone and Other Tissues (Review). Mol. Med. Rep. 2015, 11, 3212–3218.
  29. Ozer, F.F.; Dagdelen, S.; Erbas, T. Relation of RANKL and OPG Levels with Bone Resorption in Patients with Acromegaly and Prolactinoma. Horm. Metab. Res. 2018, 50, 562–567.
  30. Walsh, M.C.; Choi, Y. Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond. Front Immunol. 2014, 5, 511.